Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Adolescent

Tassiopoulos K, Landay A, Collier AC, et al. "CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies." J. Infect. Dis.. 2012;205(11):1730-8.
Collier AC, Tierney C, Downey GF, et al. "Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV." HIV Clin Trials. 2008;9(2):91-102.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." J. Infect. Dis.. 2017;215(2):238-246.
Luque AE, Cohn SE, Park J-G, et al. "Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the." Antimicrob. Agents Chemother.. 2015;59(4):2094-101.
Kallianpur AR, Hulgan T, Canter JA, et al. "Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy." AIDS. 2006;20(11):1503-13.
Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.
Hitti J, Andersen J, McComsey G, et al. "Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084." Am. J. Obstet. Gynecol.. 2007;196(4):331.e1-7.
Ferreira MAR, Mangino M, Brumme CJ, et al. "Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control." Am. J. Hum. Genet.. 2010;86(1):88-92.
Smith KY, Tierney C, Mollan K, et al. "Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine." Clin. Infect. Dis.. 2014;58(4):555-63.
Daar ES, Tierney C, Fischl MA, et al. "Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1." Ann. Intern. Med.. 2011;154(7):445-56.
Yeh T-min, Evans SR, Gulick RM, Clifford DB. "Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211." HIV Clin Trials. 2010;11(1):51-8.
Smith K, Zheng L, Bosch R, et al. "Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174." AIDS Res. Hum. Retroviruses. 2010;26(4):425-32.
Kojic EMilunka, Kang M, Cespedes MS, et al. "Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women." Clin. Infect. Dis.. 2014;59(1):127-35.
Stone ND, Dunaway SB, Flexner C, et al. "Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects." Antimicrob. Agents Chemother.. 2007;51(7):2351-8.
Crawford KW, Li C, Keung A, et al. "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)." J. Acquir. Immune Defic. Syndr.. 2010;53(5):598-605.
Cao YJun, Flexner CW, Dunaway S, et al. "Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers." Antimicrob. Agents Chemother.. 2008;52(5):1630-4.
McComsey GA, Kitch D, Sax PE, et al. "Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202." J. Acquir. Immune Defic. Syndr.. 2014;65(2):167-74.
Mugavero MJ, Pence BW, Whetten K, et al. "Childhood abuse and initial presentation for HIV care: an opportunity for early intervention." AIDS Care. 2007;19(9):1083-7.
de Perio MA, Gomez FJ, Frame PT, Fichtenbaum CJ. "A truvada hypersensitivity reaction simulating abacavir hypersensitivity." AIDS. 2007;21(16):2252-3.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
M Villarino E, Scott NA, Weis SE, et al. "Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid." JAMA Pediatr. 2015;169(3):247-55.

Pages